Oncodesign Precision Medicine (XPAR:ALOPM) DeferredTaxAndRevenue: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ALOPM Oncodesign Precision Medicine SA XPAR:ALOPM
32 GF Score
Price €0.32
GF Value €0.29
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Oncodesign Precision Medicine DeferredTaxAndRevenue?

Oncodesign Precision Medicine XPAR:ALOPM -1.23% 32 DeferredTaxAndRevenue is €0.00 Mil as of Dec. 2025. GuruFocus rates XPAR:ALOPM with a GF Score™ of 32/100 and a GF Value™ of €0.29 (Fairly Valued). The stock has 1 warning sign investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Oncodesign Precision Medicine's current deferred tax and revenue for the quarter that ended in Dec. 2025 was €0.00 Mil.

Oncodesign Precision Medicine DeferredTaxAndRevenue Related Terms

Oncodesign Precision Medicine DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Oncodesign Precision Medicine's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncodesign Precision Medicine DeferredTaxAndRevenue Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XPAR:ALOPM
32GF Score
Oncodesign Precision Medicine SA XPAR:ALOPM
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of €0.00 Mil mean?
Oncodesign Precision Medicine (XPAR:ALOPM) has a DeferredTaxAndRevenue of €0.00 Mil as of Dec. 2025. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Oncodesign Precision Medicine.
Is Oncodesign Precision Medicine's DeferredTaxAndRevenue too high?
Oncodesign Precision Medicine's current DeferredTaxAndRevenue is €0.00 Mil. Overall, Oncodesign Precision Medicine has a GF Score™ of 32/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Oncodesign Precision Medicine's DeferredTaxAndRevenue compare to VRTX and REGN?
Oncodesign Precision Medicine's DeferredTaxAndRevenue of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Oncodesign Precision Medicine. Oncodesign Precision Medicine's current DeferredTaxAndRevenue is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncodesign Precision Medicine stock overvalued right now?
Based on GuruFocus' analysis, Oncodesign Precision Medicine (XPAR:ALOPM) is currently considered Fairly Valued. The stock's GF Value™ is €0.29, compared to a current price of €0.32 — trading 10.3% above its estimated fair value. The current DeferredTaxAndRevenue is €0.00 Mil. Oncodesign Precision Medicine's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Oncodesign Precision Medicine (XPAR:ALOPM), the current DeferredTaxAndRevenue is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncodesign Precision Medicine (XPAR:ALOPM) Overvalued in 2026?

Based on GuruFocus' analysis, Oncodesign Precision Medicine stock appears to be overvalued. The current stock price of €0.32 is trading 10.3% above its estimated GF Value™ of €0.29. GuruFocus considers Oncodesign Precision Medicine to be Fairly Valued.

Key valuation signals for XPAR:ALOPM:

  • DeferredTaxAndRevenue: €0.00 Mil
  • GF Value™: €0.29 vs. price of €0.32 (10.3% above fair value)
  • GF Score™: 32/100 with 1 warning sign

No single metric tells the full story. See the XPAR:ALOPM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncodesign Precision Medicine Business Description

Other Exchanges ZR8:Germany
Address 18 rue Jean Mazen, Dijon, FRA, 21000
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.
32GF Score

Get the complete analysis for XPAR:ALOPM

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.32
Price
€0.29
GF Value